Blurbs

H.C. Wainwright Reaffirms Their Buy Rating on Wave Life Sciences (WVE)

H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Wave Life Sciences (WVEResearch Report) today and set a price target of $8.00. The company’s shares closed yesterday at $4.17.

Fein covers the Healthcare sector, focusing on stocks such as Wave Life Sciences, Unity Biotechnology, and Matinas BioPharma. According to TipRanks, Fein has an average return of -11.0% and a 34.58% success rate on recommended stocks.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Wave Life Sciences with a $10.50 average price target, implying a 151.80% upside from current levels. In a report released yesterday, Mizuho Securities also maintained a Buy rating on the stock with a $13.00 price target.

See today’s best-performing stocks on TipRanks >>

The company has a one-year high of $5.31 and a one-year low of $1.16. Currently, Wave Life Sciences has an average volume of 317.5K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Wave Life Sciences Ltd. is a biotechnology company, which engages in the development of proprietary synthetic chemistry drug. It focuses on the design, development, and commercialization of nucleic acid-based therapeutics. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.

Read More on WVE:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More